Literature DB >> 32122821

Intravascular ultrasound to guide left main stem intervention: a NOBLE trial substudy.

Andrew Ladwiniec1, Simon J Walsh, Niels Ramsing Holm, Colm G Hanratty, Timo Mäkikallio, Thomas Kellerth, David Hildick-Smith, Lone J H Mogensen, Juha Hartikainen, Ian B A Menown, Andrejs Erglis, Erlend Eriksen, Mark S Spence, Leif Thuesen, Evald Høj Christiansen.   

Abstract

AIMS: We aimed to investigate the association between the use and findings of IVUS with clinical outcomes in the PCI arm of a randomised trial of LMS PCI. METHODS AND
RESULTS: The NOBLE trial randomised patients with LMS disease to treatment by PCI or CABG. Of 603 patients treated by PCI, 435 (72%) underwent post-PCI IVUS assessment, 224 of which were analysed in a core laboratory. At five years, the composite of MACCE was 18.9% if post-PCI IVUS was performed versus 25.0% if it was not performed (p=0.45, after adjustment). Overall repeat revascularisation was not reduced (10.6% vs 16.5%, p=0.11); however, LMS TLR was (5.1% vs 11.6%, p=0.01) if IVUS was used. For comparison of stent expansion, LMS MSA was split into tertiles. We found no significant difference in MACCE, death, myocardial infarction or stent thrombosis between tertiles. There was a significant difference between the lower and upper tertiles for repeat revascularisation (17.6% vs 5.2%, p=0.02) and LMS TLR (12.2% vs 0%, p=0.002).
CONCLUSIONS: Post-PCI IVUS assessment and adequate stent expansion are not associated with reduced MACCE; however, there is an association with reduced LMS TLR. The use of intracoronary imaging to prevent stent underexpansion in LMS PCI is likely to improve outcomes.

Entities:  

Year:  2020        PMID: 32122821     DOI: 10.4244/EIJ-D-19-01003

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  8 in total

1.  A multi-center, international, randomized, 2-year, parallel-group study to assess the superiority of IVUS-guided PCI versus qualitative angio-guided PCI in unprotected left main coronary artery (ULMCA) disease: Study protocol for OPTIMAL trial.

Authors:  Giovanni Luigi De Maria; Luca Testa; Jose M de la Torre Hernandez; Dimitrios Terentes-Printzios; Maria Emfietzoglou; Roberto Scarsini; Francesco Bedogni; Ernest Spitzer; Adrian Banning
Journal:  PLoS One       Date:  2022-01-07       Impact factor: 3.240

Review 2.  Optimising PCI by Intracoronary Image-guidance.

Authors:  Mirvat Alasnag; Waqar Ahmed; Rasha Al-Bawardy; Owayed Al Shammeri; Sinjini Biswas; Thomas W Johnson
Journal:  Front Cardiovasc Med       Date:  2022-05-13

3.  Ostial lesion of the anterior descending coronary artery treated via Szabo technique supported by stent boost imaging: a case report.

Authors:  Guangliang Wang; Xuemei Wu
Journal:  J Cardiothorac Surg       Date:  2021-05-17       Impact factor: 1.637

4.  Computational and experimental mechanical performance of a new everolimus-eluting stent purpose-built for left main interventions.

Authors:  Saurabhi Samant; Wei Wu; Shijia Zhao; Behram Khan; Mohammadali Sharzehee; Anastasios Panagopoulos; Janaki Makadia; Timothy Mickley; Andrew Bicek; Dennis Boismier; Yoshinobu Murasato; Yiannis S Chatzizisis
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

Review 5.  Fundamentals of percutaneous coronary bifurcation interventions.

Authors:  Tamer Kırat
Journal:  World J Cardiol       Date:  2022-03-26

6.  Safety and Efficacy of Drug-Coated Balloons in Patients with Acute Coronary Syndromes and Vulnerable Plaque.

Authors:  Yu-Bin Zhang; Heng-Dao Liu; Jun-Hui Xing; Bo-Wen Chen; Yan-Yan Zhao; He-Ping Gu; Hai-Long Tao
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

Review 7.  The Contemporary Management of Left Main Coronary Artery Disease.

Authors:  Jonathan A Mailey; Mark S Spence
Journal:  Curr Cardiol Rev       Date:  2022

Review 8.  Physiology-Based Revascularization of Left Main Coronary Artery Disease.

Authors:  Peter Kayaert; Mathieu Coeman; Sofie Gevaert; Michel De Pauw; Steven Haine
Journal:  J Interv Cardiol       Date:  2021-02-10       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.